In patients with crizotinib-pretreated ALK+ NSCLC, alectinib has an IRC-assessed ORR of 51%, median duration of response of 14.9 months, median PFS of 8.3 months,19 and median overall survival of 29.1 months.20 Here, ALK is linked to non-small cell lung carcinoma.